BACKGROUND: The emergence of genetic data linking Nav1.7 sodium channel over- and under- expression to human pain signalling has led to an interest in the treatment of chronic pain through inhibition of Nav1.7 channels. OBJECTIVE: We describe the pharmacokinetic (PK) results of a clinical microdose study performed with four potent and selective Nav1.7 inhibitors and the subsequent modelling resulting in the selection of a single compound to explore Nav1.7 pharmacology at higher doses. METHODS: A clinical microdose study to investigate the intravenous and oral PK of four compounds (PF-05089771, PF-05150122, PF-05186462 and PF-05241328) was performed in healthy volunteers. PK parameters were derived via noncompartmental analysis. A physiologically-based PK (PBPK) model was used to predict exposure and multiples of Nav1.7 50 % inhibitory concentration (IC50) for each compound at higher doses. RESULTS:Plasma clearance, volume of distribution and bioavailability ranged from 45 to 392 mL/min/kg, 13 to 36 L/kg and 38 to 110 %, respectively. The PBPK model for PF-05089771 predicted a 1 g oral dose would be required to achieve exposures of approximately 12× Nav1.7 IC50 at maximum concentration (C max), and approximately 3× IC50 after 12 h (minimum concentration [C min] for a twice-daily regimen). Lower multiples of Nav1.7 IC50 were predicted with the same oral doses of PF-05150122, PF-05186462, and PF-05241328. In a subsequent single ascending oral dose clinical study, the predictions for PF-05089771 compared well with observed data. CONCLUSION: Based on the human PK data obtained from the microdose study and subsequent modelling, PF-05089771 provided the best opportunity to explore Nav1.7 blockade for the treatment of acute or chronic pain conditions.
RCT Entities:
BACKGROUND: The emergence of genetic data linking Nav1.7 sodium channel over- and under- expression to humanpain signalling has led to an interest in the treatment of chronic pain through inhibition of Nav1.7 channels. OBJECTIVE: We describe the pharmacokinetic (PK) results of a clinical microdose study performed with four potent and selective Nav1.7 inhibitors and the subsequent modelling resulting in the selection of a single compound to explore Nav1.7 pharmacology at higher doses. METHODS: A clinical microdose study to investigate the intravenous and oral PK of four compounds (PF-05089771, PF-05150122, PF-05186462 and PF-05241328) was performed in healthy volunteers. PK parameters were derived via noncompartmental analysis. A physiologically-based PK (PBPK) model was used to predict exposure and multiples of Nav1.7 50 % inhibitory concentration (IC50) for each compound at higher doses. RESULTS: Plasma clearance, volume of distribution and bioavailability ranged from 45 to 392 mL/min/kg, 13 to 36 L/kg and 38 to 110 %, respectively. The PBPK model for PF-05089771 predicted a 1 g oral dose would be required to achieve exposures of approximately 12× Nav1.7 IC50 at maximum concentration (C max), and approximately 3× IC50 after 12 h (minimum concentration [C min] for a twice-daily regimen). Lower multiples of Nav1.7 IC50 were predicted with the same oral doses of PF-05150122, PF-05186462, and PF-05241328. In a subsequent single ascending oral dose clinical study, the predictions for PF-05089771 compared well with observed data. CONCLUSION: Based on the human PK data obtained from the microdose study and subsequent modelling, PF-05089771 provided the best opportunity to explore Nav1.7 blockade for the treatment of acute or chronic pain conditions.
Authors: Neil Castle; David Printzenhoff; Shannon Zellmer; Brett Antonio; Alan Wickenden; Christopher Silvia Journal: Comb Chem High Throughput Screen Date: 2009-01 Impact factor: 1.339
Authors: Hannah M Jones; Hugh A Barton; Yurong Lai; Yi-An Bi; Emi Kimoto; Sarah Kempshall; Sonya C Tate; Ayman El-Kattan; J Brian Houston; Aleksandra Galetin; Katherine S Fenner Journal: Drug Metab Dispos Date: 2012-02-16 Impact factor: 3.922
Authors: Brian A Sparling; S Yi; J Able; H Bregman; Erin F DiMauro; R S Foti; H Gao; A Guzman-Perez; H Huang; M Jarosh; T Kornecook; J Ligutti; B C Milgram; B D Moyer; B Youngblood; V L Yu; M M Weiss Journal: Medchemcomm Date: 2016-12-02 Impact factor: 3.597
Authors: M Flinspach; Q Xu; A D Piekarz; R Fellows; R Hagan; A Gibbs; Y Liu; R A Neff; J Freedman; W A Eckert; M Zhou; R Bonesteel; M W Pennington; K A Eddinger; T L Yaksh; M Hunter; R V Swanson; A D Wickenden Journal: Sci Rep Date: 2017-01-03 Impact factor: 4.379
Authors: Anthony J Roecker; Mark E Layton; Joseph E Pero; Michael J Kelly; Thomas J Greshock; Richard L Kraus; Yuxing Li; Rebecca Klein; Michelle Clements; Christopher Daley; Aneta Jovanovska; Jeanine E Ballard; Deping Wang; Fuqiang Zhao; Andrew P J Brunskill; Xuanjia Peng; Xiu Wang; Haiyan Sun; Andrea K Houghton; Christopher S Burgey Journal: ACS Med Chem Lett Date: 2021-06-01 Impact factor: 4.632